When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Distinguishing indolent from advanced systemic mastocytosis is notoriously complex, even for seasoned clinicians. To simplify diagnosis, researchers developed a mathematical model using basic lab values, achieving 93% predictive…
In this episode of the Oncology Brothers podcast hosted by Rohit Gosain, MD and Rahul Gosain, MD speak to Jorge Cortes, MD, from the Georgia Cancer Center, joins…
Hematologist-oncologist and author Vinay Prasad, MD, MPH, dismantles claims that ivermectin and fenbendazole are miracle cancer cures, while also criticizing the FDA’s approval process for expensive anti-cancer drugs…
Jimmy Ruiz, MD, reflects on his career journey in North Carolina and the transformative progress in lung cancer treatment. Early in his career, limited tools like chemotherapy presented…
David Simel, MD, and William Kim, MD, explore renal cell carcinoma in this JAMA Clinical Review podcast. They discuss key insights from the 2019 Nobel Prize research on…
Advances in non-small cell lung cancer (NSCLC) treatment have transformed care from a one-size-fits-all approach in the 1990s to highly personalized regimens today. Treatment now considers actionable mutations…
Faith Davies, MD, shares insights from the IMS 2024 session on high-risk disease, highlighting the debut of a unified high-risk definition. This new framework incorporates 17p deletions, mutations,…
The dialogue between Venugopal, MD, and Nabhan, MD, delves into unresolved challenges in treating chronic myeloid leukemia (CML). Venugopal emphasizes the need for targeted therapies in CML blast…
Lobular breast cancer presents unique challenges in detection and treatment due to its diffuse growth pattern and differences from ductal cancers. Liz O’Riordan, MD, shares her personal journey,…
Tune in for this comprehensive overview of Chronic Lymphocytic Leukemia (CLL), covering key risk factors, symptoms, and the decision-making process between monitoring and initiating treatment. This episode also…
